Author

Magdalena Szymanik-Resko

Observed names: M. Szymanik-Resko, Szymanik-Resko Magdalena

Observed institution: Szpital Morski im. PCK

OpenAlex ID: A5120272306

Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+/HER2− advanced breast cancer: A multicenter retrospective study

2025 · Renata Duchnowska, Katarzyna Soter, et al. · The Breast · 8

Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe

2026 · Małgorzata Pieniążek, Anna Polakiewicz-Gilowska, et al. · The Oncologist · 3

Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study

2026 · Justyna Żubrowska, Małgorzata Pieniążek, et al. · Journal of Neuro-Oncology · 2

566P Effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer: A real-world retrospective cohort study from central Europe

2025 · M. Pieniazek, M. Puskulluoglu, et al. · Annals of Oncology · 2

PDF

Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study

2026 · Aleksandra Konieczna, Małgorzata Pieniążek, et al. · The Oncologist · 1

Correction to: Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort

2026 · Mirosława Püsküllüoğlu, Anna Polakiewicz-Gilowska, et al. · Supportive Care in Cancer

PDF

Sacituzumab govitecan in heavily pretreated metastatic triple-negative breast cancer: a secondary analysis of the CEBCC-102 real-world cohort

2026 · Kubeczko Marcin, Konieczna Aleksandra, et al. · BMC Cancer

Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort

2026 · Mirosława Püsküllüoğlu, Anna Polakiewicz-Gilowska, et al. · Supportive Care in Cancer

PDF

Treatment outcomes with pembrolizumab and chemotherapy in metastatic metaplastic triple-negative breast cancer: Data from a central European cohort.

2026 · Justyna Żubrowska, Malgorzata Podskarbi, et al. · Journal of Clinical Oncology

PDF

Treatment-emergent thyroid disorders and outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer: A real-world study.

2026 · Malgorzata Podskarbi, Aleksandra Konieczna, et al. · Journal of Clinical Oncology

Real-world effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients aged ≥65 years with metastatic triple-negative breast cancer.

2026 · Aleksandra Konieczna, Malgorzata Meluch, et al. · Journal of Clinical Oncology

Abstract PS5-02-20: Treatment patterns and outcomes of sacituzumab govitecan in older versus younger patients with mTNBC: multinational real-world data

2026 · A. Konieczna, M. Holanek, et al. · Clinical Cancer Research

Abstract PS1-08-01: Safety of Combining Radiotherapy With Sacituzumab Govitecan in Patients With Advanced Triple-Negative Breast Cancer: An International Multicenter Cohort Study

2026 · A. Polakiewicz-Gilowska, M. Pieniążek, et al. · Clinical Cancer Research

Abstract PS2-04-15: Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from a central European cohort

2026 · J. Żubrowska, M. Kubeczko, et al. · Clinical Cancer Research

Abstract PS5-03-08: Effectiveness of sacituzumab govitecan in later-line treatment of mTNBC: real-world evidence from Poland, Czech Republic, and Slovakia according to prior first-line pembrolizumab use

2026 · J. Żubrowska, M. Kubeczko, et al. · Clinical Cancer Research

Abstract PS1-05-12: Primary G-CSF Prophylaxis in Sacituzumab Govitecan-Treated mTNBC: Real-World Evidence from a Multinational Cohort

2026 · Z. Bielčiková, M. Pieniążek, et al. · Clinical Cancer Research

Abstract PS5-03-04: Timing of final oncologist visit and systemic treatment use near the end of life in advanced triple-negative breast cancer: a multinational cohort study

2026 · J. Zubrowska, M. Holanek, et al. · Clinical Cancer Research

Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort

2026 · Karolina Winsko-Szczęsnowicz, Małgorzata Pieniążek, et al. · Clinical & Translational Oncology

Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study

2026 · Justyna Żubrowska, Małgorzata Pieniążek, et al. · The Breast

PDF

Impact of Germline BRCA1/2 Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan—An International CEBCC Study from Poland, the Czech Republic and Slovakia

2026 · Renata Pacholczak-Madej, Mirosława Püsküllüoğlu, et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics

Works count: 20

Citation count: 16

H-index: 2

I10-index: